| Chavez et al. 2024(1) - Meta-analysis |
Meta-analysis of 14 RCTs comparing SLT with eyedrops in OAG/OHT |
1706 patients (936 were subjected to SLT) |
1 month to ≥5 years |
IOP, % with ≥20% drop, number of meds, side effects |
SLT and eye-drop application lowered IOP; patients needed fewer medications (-1.09); fewer side effects and surgeries |
| Jang et al. 2021(2) - meta-analysis |
Meta-analysis of 12 studies (9 included in the pooled analysis) assessing repeat SLT in adult POAG |
1371 eyes |
Up to 24 months |
IOP reduction and safety profile (standardized mean difference) |
Good IOP reduction with repeat SLT across all time points (up to 2 years); safe and effective |
| Hong et al. 2009(3) |
Retrospective review of OAG patients (POAG/PXG/PG) treated with repeat 360° SLT after ≥6 months of good response to the first SLT. No prior ALT or glaucoma surgery |
44 eyes / 35 patients |
1-8 months |
IOP change and % of eyes with ≥20% IOP reduction after the first and second SLT |
IOP drop: 5.0 mmHg (1st SLT) vs. 2.9 mmHg (2nd SLT); similar success rate; the time between SLTs did not influence the outcomes |
| Francis et al. 2016(4) |
Multicenter retrospective study involving patients with primary or secondary OAG who underwent a second 360° SLT after IOP increase ≥6 months after the first |
137 eyes |
12 months |
IOP at 6 and 12 months; number of medications used |
12-month IOP: 16.4 mmHg (1st) vs. 16.7 mmHg (2nd); similar pressure reduction; meds unchanged |
| Garg et al. 2020(5) (LiGHT UK) |
Post hoc analysis of the LiGHT RCT. Included treatment-naïve patients with OAG or OHT who needed a second SLT within 18 months |
115 eyes / 90 patients |
18 months |
Change in IOP at 2 months; time to further intervention |
2nd SLT started from the lower baseline IOP; still showed better pressure drop at 2 months; 67% remained drop-free |
| Realini et al. 2021(6) - COAST (rational) |
RCT protocol evaluating annual low-energy SLT. No clinical outcomes yet |
- |
- |
No clinical outcomes available yet |
No results yet-study rationale only |
| Rolim-de-Moura et al. 2022(7) - Cochrane |
Systematic review of 40 RCTs comparing laser (including repeat SLT) and medications or surgery in OAG/OHT |
5613 eyes |
Up to 5 years |
IOP control, visual field progression, side effects |
Repeat SLT worked well and safely; similar to modern drops in IOP control and better cost-effectiveness |
| Yang et al. 2024(8) (LiGHT China) |
Post hoc analysis of LiGHT China RCT. Included treatment-naïve OAG/OHT patients with repeat SLT as first-line therapy |
180 eyes / 105 patients |
2 years / time to failure |
Change in IOP, effect duration, % of responders |
2nd SLT led to the same IOP levels as the 1st (final ~16 mmHg); longer-lasting results after the 2nd (HR 0.38); 85% demonstrated good response |